CASI Pharmaceuticals, Inc.
CASIF
$0.10
$0.00-2.38%
OTC PK
| 12/31/2025 | 09/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.22M | 3.08M | 6.24M | 6.24M | 13.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.22M | 3.08M | 6.24M | 6.24M | 13.36M |
| Cost of Revenue | 3.53M | 2.37M | 2.62M | 2.62M | 10.13M |
| Gross Profit | 3.69M | 706.00K | 3.62M | 3.62M | 3.23M |
| SG&A Expenses | 14.11M | 9.54M | 11.92M | 11.92M | 11.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -5.00K | -5.00K | -2.00K |
| Total Operating Expenses | 18.88M | 13.32M | 16.47M | 16.47M | 25.71M |
| Operating Income | -11.65M | -10.24M | -10.23M | -10.23M | -12.35M |
| Income Before Tax | -13.04M | -10.88M | -10.75M | -10.75M | -14.37M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.04M | -10.88M | -10.75M | -10.75M | -14.37M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.04M | -10.88M | -10.75M | -10.75M | -14.37M |
| EBIT | -11.65M | -10.24M | -10.23M | -10.23M | -12.35M |
| EBITDA | -11.34M | -9.66M | -9.65M | -9.65M | -11.77M |
| EPS Basic | -0.48 | -0.68 | -0.69 | -0.69 | -0.75 |
| Normalized Basic EPS | -0.30 | -0.42 | -0.42 | -0.42 | -0.40 |
| EPS Diluted | -0.48 | -0.68 | -0.69 | -0.69 | -0.75 |
| Normalized Diluted EPS | -0.30 | -0.42 | -0.42 | -0.42 | -0.40 |
| Average Basic Shares Outstanding | 27.10M | 16.05M | 15.49M | 15.49M | 19.15M |
| Average Diluted Shares Outstanding | 27.10M | 16.05M | 15.49M | 15.49M | 19.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |